arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CRISPR Therapeutics AG

CRSP
$59.01 ▲ +0.66 (+1.13%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
46 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

CRISPR Therapeutics AG faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.7B
Dividend Yield
Revenue Growth 1041.4%
Op. Margin None
ROIC -5.1%
FCF / Share $-0.87
Trailing P/E
Price / Book 3.3x
FCF Yield
Debt / Equity 0.34
info Valuation on last close. End-of-day price, Sep 22, 2026.

46-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$10.18M
↑ +1041.4%
Net Income Profit after all expenses
$-122.93M
↑ +9.6%
Operating Margin Operating profit as % of sales
-181.0%
↓ -623.3%
FCF / Share Free cash flow per share
$-0.87
↑ +33.4%
Long-Term Debt Long-term obligations
$586.20M
— +0.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
23
Cash Quality
44

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 13 years · 46 quarters